パリセード・バイオ
Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.05 | $500,000 | -$8M |
| 2026 Q1 | -0.05 | $0 | -$4M |
| 2025 Q4 | -0.06 | $0 | -$3M |
| 2025 Q3 | -0.38 | $0 | -$4M |
| 2025 Q2 | -0.58 | $0 | -$2M |
| 2025 Q1 | -0.46 | $0 | -$2M |
| 2024 Q4 |
| -0.57 |
| $0 |
| -$2M |
| 2024 Q3 | -2.32 | $0 | -$3M |